[{"data":1,"prerenderedAt":189},["ShallowReactive",2],{"drug-naratriptan":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":42,"contraindications":73,"warnings":91,"renal":99,"monitoring":107,"interactions":108,"review":109,"examples":112,"atc":118,"iran":120,"usApproval":132,"links":138,"populations":154},"naratriptan",1,{"fa":7,"en":8},"ناراتریپتان","Naratriptan","nervous-system",{"fa":11,"en":12},"تریپتان (آگونیست 5-HT1B\u002F1D)","Triptan (5-HT1B\u002F1D agonist)",[14],{"name":15,"market":16},"Amerge","US",[18,19,7],"amerge","naramig",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-2-5","tablet","oral","2.5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},2.5,"mg",false,[16],[32],{"source":33,"section":34},"fda-naratriptan","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":39,"refs":40},"tab-1","1 mg tablet",{"amount":5,"unit":28,"perUnit":23,"scored":29},[16],[41],{"source":33,"section":34},[43],{"id":44,"disease":45,"label":46,"population":49,"type":53,"unit":28,"dose":54,"refs":55,"limits":58,"notes":62},"acute","migraine-acute",{"fa":47,"en":48},"حمله حاد میگرن بزرگسال — ۱ یا ۲٫۵ mg","Acute migraine, adults — 1 or 2.5 mg",{"minAge":50},{"value":51,"unit":52},18,"year","fixed",{"perDose":5,"perDoseMax":27,"dosesPerDay":5},[56],{"source":33,"section":57},"2.1",{"maxPerDay":59,"refs":60},5,[61],{"source":33,"section":57},[63],{"text":64,"refs":67},{"fa":65,"en":66},"اگر بازگشت یا پاسخ نسبی: یک بار پس از ۴ ساعت تکرار؛ حداکثر ۵ mg در ۲۴ ساعت. نارسایی خفیف\u002Fمتوسط کلیه یا کبد: شروع ۱ mg، حداکثر ۲٫۵ mg\u002Fروز.","If it returns or partial response: repeat once after 4 h; max 5 mg in 24 h. Mild\u002Fmoderate renal or hepatic impairment: start 1 mg, max 2.5 mg\u002Fday.",[68,69,71],{"source":33,"section":57},{"source":33,"section":70},"2.2",{"source":33,"section":72},"2.3",[74,83],{"id":75,"severity":76,"text":77,"refs":80},"ci","block",{"fa":78,"en":79},"بیماری ایسکمیک کرونر یا وازواسپاسم کرونر (پرینزمتال)؛ WPW یا آریتمی مسیر فرعی؛ سابقه سکته، TIA یا میگرن همی‌پلژیک\u002Fبازیلار؛ بیماری عروق محیطی؛ بیماری ایسکمیک روده؛ فشار خون کنترل‌نشده؛ تریپتان یا ارگوت دیگر ظرف ۲۴ ساعت؛ حساسیت.","Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic\u002Fbasilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity.",[81],{"source":33,"section":82},"4",{"id":84,"severity":76,"text":85,"refs":88},"organ",{"fa":86,"en":87},"نارسایی شدید کلیه (ClCr زیر ۱۵) یا کبد (Child-Pugh C).","Severe renal impairment (CrCl \u003C15) or severe hepatic impairment (Child-Pugh C).",[89,90],{"source":33,"section":70},{"source":33,"section":72},[92],{"text":93,"refs":96},{"fa":94,"en":95},"ایسکمی و انفارکتوس قلب؛ آریتمی؛ احساس فشار قفسه سینه، گلو یا فک؛ رویداد عروق مغزی؛ سردرد ناشی از مصرف زیاد دارو؛ سندرم سروتونین؛ افزایش فشار خون.","Myocardial ischaemia and infarction; arrhythmias; chest\u002Fthroat\u002Fjaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure.",[97],{"source":33,"section":98},"5",[100],{"egfrBelow":101,"severity":76,"text":102,"refs":105},15,{"fa":103,"en":104},"ClCr زیر ۱۵: منع مصرف.","CrCl \u003C15: contraindicated.",[106],{"source":33,"section":70},[],[],{"status":110,"reviewer":111,"date":111},"unverified",null,[113],{"regimen":44,"formulation":36,"input":114,"expect":117},{"ageYears":115,"weightKg":116},35,65,{"perDose":5,"tabletsPerDoseRounded":5},[119],"N02CC02",{"status":121,"forms":122,"refs":127},"registered",[123],{"code":124,"en":125,"fa":126},"13612","NARATRIPTAN 2.5MG TAB","قرص ناراتریپتان ۲٫۵ میلی‌گرم",[128],{"source":129,"section":130,"url":131},"darooyab-generic","G-860\u002FNaratriptan","https:\u002F\u002Fwww.darooyab.ir\u002FG-860\u002FNaratriptan",{"kind":133,"refs":134,"id":137},"ANDA",[135],{"source":33,"section":136},"SPL approval \u002F marketing category","ANDA091441",[139,142,146,149,152],{"kind":140,"url":141,"label":137},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=091441",{"kind":143,"url":144,"label":145},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda","FDA Naratriptan",{"kind":147,"url":148,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601083.html",{"kind":150,"url":151,"label":119},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CC02",{"kind":153,"url":131,"label":8},"darooyab",{"pregnancy":155,"lactation":164,"pediatric":172,"geriatric":181},{"level":156,"text":157,"quote":160,"refs":161},"caution",{"fa":158,"en":159},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women.",[162],{"source":33,"section":163},"8.1",{"level":156,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of naratriptan in human milk, the effects of naratriptan on the breastfed infant, or the effects of naratriptan on milk production.",[170],{"source":33,"section":171},"8.2",{"level":173,"text":174,"quote":177,"refs":178},"not-established",{"fa":175,"en":176},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[179],{"source":33,"section":180},"8.4",{"level":156,"text":182,"quote":185,"refs":186},{"fa":183,"en":184},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",[187],{"source":33,"section":188},"8.5",1792191556810]